Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

58.39 +0.85 (+1.48%)
Streaming Delayed Price Updated: 12:46 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. 
Via Investor's Business Daily
NASDAQ:HALO, a growth stock which is not overvalued.
NASDAQ:HALO stands out as a growth opportunity that won't break the bank. 
Via Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO. 
Via Chartmill
Expert Ratings For Halozyme Therapeutics
Via Benzinga
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Halozyme Therapeutics +13% On Thursday: What's Going On?
Halozyme Therapeutics surges as it raises FY24 guidance, driven by increased revenue projections and a new European patent for its drug delivery platform. 
Via Benzinga
Topics Intellectual Property
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): a strong growth stock preparing for the next leg up?. 
Via Chartmill
NASDAQ:HALO is not too expensive for the growth it is showing.
NASDAQ:HALO stands out as a growth opportunity that won't break the bank. 
Via Chartmill
9 Analysts Have This To Say About Halozyme Therapeutics
Via Benzinga
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
Via Benzinga
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
Via Benzinga
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. 
Via Chartmill
The 3 Best Biotech Stocks to Buy in May 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May. 
Via InvestorPlace
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now. 
Via InvestorPlace
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results. 
Via Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.